- Home
- UBSI vs BLCO Comparison
UBSI vs BLCO Comparison
Compare UBSI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- BLCO
- Stock Information
- Founded
- UBSI 1982
- BLCO 1853
- Country
- UBSI United States
- BLCO Canada
- Employees
- UBSI N/A
- BLCO N/A
- Industry
- UBSI Major Banks
- BLCO Ophthalmic Goods
- Sector
- UBSI Finance
- BLCO Health Care
- Exchange
- UBSI Nasdaq
- BLCO Nasdaq
- Market Cap
- UBSI 4.9B
- BLCO 4.0B
- IPO Year
- UBSI N/A
- BLCO 2022
- Fundamental
- Price
- UBSI $35.49
- BLCO $11.28
- Analyst Decision
- UBSI Hold
- BLCO Hold
- Analyst Count
- UBSI 4
- BLCO 12
- Target Price
- UBSI $40.13
- BLCO $15.59
- AVG Volume (30 Days)
- UBSI 831.5K
- BLCO 1.1M
- Earning Date
- UBSI 04-24-2025
- BLCO 04-30-2025
- Dividend Yield
- UBSI 4.17%
- BLCO N/A
- EPS Growth
- UBSI 2.88
- BLCO N/A
- EPS
- UBSI 2.70
- BLCO N/A
- Revenue
- UBSI $1,039,896,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- UBSI $17.97
- BLCO $6.30
- Revenue Next Year
- UBSI $6.13
- BLCO $5.56
- P/E Ratio
- UBSI $13.17
- BLCO N/A
- Revenue Growth
- UBSI 2.67
- BLCO 11.94
- 52 Week Low
- UBSI $30.51
- BLCO $10.45
- 52 Week High
- UBSI $44.43
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- UBSI 59.82
- BLCO 38.54
- Support Level
- UBSI $34.69
- BLCO $10.83
- Resistance Level
- UBSI $36.00
- BLCO $11.78
- Average True Range (ATR)
- UBSI 0.77
- BLCO 0.59
- MACD
- UBSI 0.23
- BLCO -0.03
- Stochastic Oscillator
- UBSI 82.83
- BLCO 23.58
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.